Americans injured in Iraq, and families of those killed or injured, allege that medical-supply contracts helped finance attacks. The companies dispute the allegations and ask the Supreme Court to require a closer link between their transactions and specific attacks.
Iraq war victims allege that 21 drug and device makers, including AstraZeneca, GE HealthCare, Roche and Genentech, Johnson & Johnson and its units, Pfizer and its units, and Viatris Pharmaceuticals LLC paid millions in bribes to a militia. Their Supreme Court brief alleges that those bribes “directly financed Jaysh al-Mahdi’s attacks on Americans in Iraq” and that the militia was so dependent on Health Ministry resources that it was known in Iraq as “The Pill Army.” On November 9, the justices invited the Solicitor General, the federal government’s lawyer at the Court, to give the government’s views before they decide whether to hear the companies’ appeal, the U.S. Supreme Court docket shows. Lawyers call that step a CVSG, short for a call for the views of the Solicitor General. It is not a grant of review, the docket sets no deadline for the government’s brief, and the companies’ petition stays pending.
The companies give a sharply different account. Their petition says they did business with Iraq’s Health Ministry at the U.S. government’s request and describes the commissions and extra goods as standard contracting practice, not bribes. They argue that aiding-and-abetting liability, the law’s term for helping a terrorist attack, requires aid tied to a specific attack or aid that is systemic and pervasive, plus a desire to help the attacks succeed. The plaintiffs say the companies knew the payments and goods would reach Jaysh al-Mahdi, the militia the plaintiffs allege controlled the ministry.
The 4 sources behind this story: 3 court records and 1 other source, each linked with what it shows. Free with the weekly Litigation Sentinel brief.
Joshua Atchley and the other plaintiffs are U.S. service members, civilians who served in Iraq, and family members. They sued in 2017 under the Anti-Terrorism Act, seeking three times any damages they establish. According to the companies’ petition, the plaintiffs tie their claims to more than 300 alleged Jaysh al-Mahdi attacks between 2005 and 2011.
The plaintiffs’ brief describes two alleged routes for support. It says payments to ministry officials reached the militia and extra batches of medical goods were diverted, sold, or used to compensate fighters. The brief alleges that the companies continued these arrangements despite signs that the ministry’s resources supported attacks on Americans. It describes explosives designed to pierce tank armor among the weapons used against the plaintiffs.
The petition counters that the goods served a functioning health ministry, that extra supplies followed standard bid instructions, and that ministry officials or militia members allegedly diverted resources after the companies’ transactions.
Free weekly intelligence for executives responsible for litigation exposure: the named decision-makers, dollar exposure, operating consequence, and next development.
A federal district court dismissed the claims in 2020. The U.S. Court of Appeals for the District of Columbia Circuit reversed, holding that the complaint’s allegations were sufficient to proceed. That was a ruling about what the plaintiffs had pleaded, not a finding that the alleged bribes or financing occurred.
The Supreme Court then decided *Twitter v. Taamneh*, a case about when a defendant can be liable for helping a terrorist attack. In 2024, the Court granted the companies’ earlier petition, vacated the appeals court’s judgment and sent this case back for another look under *Taamneh*. On January 23, 2026, the D.C. Circuit again allowed the claims to proceed; it denied rehearing on April 23.
Now the companies say the appeals court still permits liability for aid that is neither tied to a specific attack nor systemic and pervasive, and without any showing that they wanted the attacks to succeed. They also challenge the separate claim that their transactions directly caused the plaintiffs’ injuries. The plaintiffs respond that their complaint traces cash and goods through the allegedly captured ministry to the militia’s weapons, fighters, and operations. In their view, the pleaded connection is more specific than general support for a group.
**P&L translation:** The Anti-Terrorism Act triples any damages the plaintiffs prove, and the D.C. Circuit’s ruling lets them pursue claims tied to more than 300 alleged attacks before any trial tests the facts. For a company that sells to a foreign government ministry, the standard the justices may set could decide whether a suit over where that ministry’s money went ends on a motion to dismiss or moves into discovery, the costly exchange of internal records.
The Solicitor General has weighed in once before. After *Taamneh*, the government recommended sending the case back to the appeals court to reconsider its ruling, but opposed full Supreme Court review at that time. The justices followed that advice. The appeals court’s second ruling is the one the companies now ask them to review.
The November 9 invitation asks for the government’s view on that renewed request. It is a pause before the justices choose whether to hear the appeal, not a judgment on the companies’ conduct or the plaintiffs’ claims. The Solicitor General’s brief, when filed, will give that view on the docket. A denial of review would leave in place the D.C. Circuit’s ruling for the plaintiffs, who have now won twice in that court. A grant would put the core question before the Court, the link Joshua Atchley and the other plaintiffs must show between the companies’ Iraq dealings and the attacks behind the suit.
The readiness check has five questions about your reported litigation practices. Use the summary to choose an operating question to explore.
Take the 2-minute readiness check →Free weekly intelligence for executives responsible for litigation exposure: the named decision-makers, dollar exposure, operating consequence, and next development.